|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION |
WASHINGTON, D.C. 20549 |
_________________________
FORM 8-K |
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
THE SECURITIES EXCHANGE ACT OF 1934 |
Date of report (Date of earliest event reported): December 16, 2008 |
CHAMPIONS BIOTECHNOLOGY, INC. |
(Exact name of registrant as specified in its charter) |
Delaware | 0-17263 | 52-1401755 |
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer |
of Incorporation) | Identification No.) |
1400 North 14th Street, Arlington, Virginia 22209 |
(Address of Principal Executive Offices) |
Registrant’s telephone number, including area code: (410) 630-1313 |
Inapplicable |
(Former Name or Former Address if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
INFORMATION TO BE INCLUDED IN THE REPORT |
.
On December 16, 2008, Champions Biotechnology, Inc. (the “Company”) announced its results of operations for its fiscal quarter ended October 31, 2008. A copy of the Company’s press release announcing such results dated December 16, 2008 is attached hereto as Exhibit 99.1. This Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission (“SEC”) and shall not be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Securities Act of 1933. |
Item 9.01. | Financial Statements and Exhibits. |
(c) | Exhibits |
The following exhibits are filed herewith: |
Exhibit No. |
99.1 | Press Release dated December 16, 2008 |
SIGNATURES |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. |
CHAMPIONS BIOTECHNOLOGY, INC. |
(Registrant) |
Date: December 16, 2008 | By: | /s/ Douglas D. Burkett |
Douglas D. Burkett | ||
President |
|
Exhibit 99.1 | |
Champions Biotechnology, Inc. | NEWS |
1400 North 14th Street, Arlington, Virginia 22209 USA. Tel. 410-630-1313
|
Highlights of the first quarter are: |
(1) The Company grew its preclinical platform by expanding its collaborations to acquire tumor samples and by implanting, propagating and storing banks of Biomerk Tumorgrafts for use in future analysis of oncology drugs. |
(2) The growing platform of Biomerk Tumorgrafts generated growing interest and use of the Company’s technology from large and small pharmaceutical and biotechnology companies. |
(3) The Company grew its Personalized Oncology business and plans to make this service available in key international markets. |
(4) The Company expanded initiatives to grow its own drug pipeline. During the quarter, the Company engaged the services of additional personnel to identify drug candidates; numerous candidates were identified, discussions were initiated, and the Company is currently performing due diligence on a number of agents for acquisition or co development partnerships. |
For more information regarding Champions Biotechnology please visit our web site at www.championsbiotechnology.com. |
About Champions Biotechnology, Inc. |
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company’s Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts™) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. |
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to Companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery. |
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally |
This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company’s actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology’s Form 10-KSB for the fiscal year ended April 30, 2008 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology’s future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology’s expectations, except as required by law. |
CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.com |
Contact: |
The Investor Relations Group, Inc. |
Adam Holdsworth/James Carbonara, 212-825-3210 |
or |
Public Relations |
Susan Morgenbesser/Janet Vasquez, 212-825-3210 |